Nasdaq
$8.50▲ 1.92%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $76.2MShares out 9.0M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
4- 10.6After-hours26.10.07 06:044Ownership#●●●
ProMIS Neurosciences Inc.
Insider Ivana Rubino of ProMIS Neurosciences Inc. reported a change in beneficial ownership of securities as of October 5, 2026. This filing is a standard notification of insider share transactions via Form 4.…more
$8.50+1.92%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.6After-hours26.10.07 06:033Ownership
ProMIS Neurosciences Inc.
Ivana Rubino, an officer of ProMIS Neurosciences, has executed a limited power of attorney for SEC filings. This grants Max Milbury and Neil Warma the authority to prepare and file SEC forms, including Form 3, 4, 5, and Schedule 13D/13G, on her behalf.…more
$8.50+1.92%vs prev closeView filingShare - 8.7After-hours26.08.08 05:004Ownership
ProMIS Neurosciences Inc.
ProMIS Neurosciences Inc.의 내부자인 Johanne Kaplan이 2026년 8월 5일 자로 주식 보유 현황 변동을 보고하는 Form 4 공시를 제출했습니다. 본 공시는 해당 임원의 증권 소유권 변동 사항을 SEC에 공식적으로 알리는 절차입니다.…more
$8.50+1.92%vs prev closeView filingShare
3 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.6Pre-market26.10.06 20:05#●●●#●●●
ProMIS Neurosciences Appoints Alzheimer’s Expert Ivana Rubino as CCO
ProMIS Neurosciences has appointed former Biogen and Roche executive Dr. Ivana Rubino as Chief Commercial Officer. The appointment aims to strengthen commercial leadership as the company prepares for the 12-month topline data readout of its Alzheimer's candidate, PMN310, in Q1 2027.…more
$8.50+1.92%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.1Pre-market26.09.01 21:00
●●●●●●●● ●●●●● ●●●●●●
ProMIS Neurosciences announced its participation in several investor conferences throughout September to discuss its PMN310 Alzheimer's candidate and technology platform. This is a routine investor relations activity and does not provide immediate material impact on the stock price.…more
$8.50+1.92%vs prev close - 8.13After-hours26.08.14 05:00
●●●●●●●● ●●●●● ●●●●●●
ProMIS Neurosciences announced positive interim safety and biomarker data for its Alzheimer's drug candidate, PMN310, showing a favorable safety profile. The company maintains a strong cash position of $53.4 million, sufficient to fund operations through 2027.…more
$8.50+1.92%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report